Antibodies that bind to EphA2 and methods of use thereof

Details Antibodies that bind to EphA2 and methods of use thereof Antibodies that bind to EphA2 and methods of use thereof

2006-02-06

2009-08-04

Yaen, Christopher H (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C435S326000, C424S130100

Reexamination Certificate

active

07569672

ABSTRACT:
Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5656444 (1997-08-01), Webb et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6210671 (2001-04-01), Co
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6350861 (2002-02-01), Co et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 6541225 (2003-04-01), Li
patent: 6927203 (2005-08-01), Kinch et al.
patent: 2006/0034856 (2006-02-01), Kosmatopoulos et al.
patent: 0519596 (1992-12-01), None
patent: 0519596 (1992-12-01), None
patent: WO-00/37503 (2000-06-01), None
patent: WO-01/12172 (2001-02-01), None
patent: WO-01/12840 (2001-02-01), None
patent: WO-01/12840 (2001-02-01), None
patent: WO-01/27160 (2001-04-01), None
patent: WO-01/43869 (2001-06-01), None
patent: WO-01/43869 (2001-06-01), None
patent: WO-03/091383 (2003-11-01), None
patent: WO-03/091383 (2003-11-01), None
patent: WO-03/094859 (2003-11-01), None
patent: WO-03/094859 (2003-11-01), None
patent: WO-2004/014292 (2004-02-01), None
patent: WO-2004/014292 (2004-02-01), None
Kinch, M.S. et al. (2003). “Overexpression and Functional Alterations of the EphA2 Tyrosine Kinase in Cancer,”Clinical&Experimental Metastasis20(1):59-68.
Supplementary European Search Report issued on May 2, 2008 for EP application 06734397.0, filed on Feb. 6, 2006, 3 pages.
Aruffo, A. et al. (Dec. 1987). “Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System,”Proc. Natl. Acad. Sci. USA84:8573-8577.
Bartley, T.D. et al. (Apr. 7, 1994). “B61 is a Ligand for the ECK Receptor Protein-Tyrosine Kinase,”Nature368-558-560.
Bird, R.E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Brown, B.A. et al. (Jul. 1, 1987). “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Res.47:3577-3583.
Carles-Kinch, K. et al. (May 15, 2002). “Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior,”Cancer Res. 62:2840-2847.
Daugherty, B.L. et al. (1991). “Polymerase Chain Reaction Facilitates the Cloning, CDR- Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins,”Nucl. Acids Res. 19(9):2471-2476.
Dillman, R.O. et al. (Nov. 1, 1988). “Superiority of an Acid-Labile Daunorubicin- Monoclonal Antibody Immunoconjugate Compared to Free Drug,”Cancer Res. 48:6097-6102.
Duxbury, M.S. et al. (2004). “Ligation of EphA2 by Ephrin A1-Fc Inhibits Pancreatic Adenocarcinoma Cellular Invasiveness,”Biochemical and Biophysical Research Communications320:1096-1102.
Easty, D.J. et al. (1995). “Abnormal Protein Tyrosine Kinase Gene Expression During Melanoma Progression and Metastasis,”Int. J. Cancer60:129-136.
Gennaro, A.R. ed. (2000).Remington: The Science and Practice of Pharmacy20th Edition, Lippincott Williams and Wilkins, pp. xiv-xv (Table of Contents Only.).
Goldenberg, D.M. ed. (1995).Cancer Therapy With Radiolabeled Antibodies, CRC Press: Boca Raton, FL, two pages. (Table of Contents Only.).
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature321:522-525.
Kane, S. et al. (Jun. 21, 2002). “A Method to Identify Serine Kinase Substrates,”J. Bio. Chem. 277(25):22115-22118.
Köhler, G. et al. (Aug. 7, 1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-497.
Lindberg, R.A. et al. (Dec. 1990). “cDNA Cloning and Characterization ofeck, an Epithelial Cell Receptor Protein-Tyrosine Kinase in theeph/elkFamily of Protein Kinases,”Mol. Cell. Biol. 10(12):6316-6324.
LoBuglio, A.F. et al. (Jun. 1989). “Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response,”Proc. Natl. Acad. Sci.USA86:4420-4424.
Mahato, R.I. et al. (1997). “Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives,”Pharm. Res. 14(7):853-859.
Mangham, D.C. et al. (1999). “A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA),”Histopathology35(2):129-133.
Riechmann, L. et al. (Mar. 24, 1988). “Reshaping Human Antibodies for Therapy,”Nature332:323-327.
Rosenberg, I.M. et al. (1997). “Epithelial Cell Kinase-B61: An Autocrine Loop Modulating Intestinal Epithelial Migration and Barrier Function,”Am. J. Physiol. 273:G824-G832.
Shaw, D.R. et al. (Jun. 15, 1987). “Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen,”J. Immunology138(12):4534-4538.
Shen, W-C. et al. (Oct. 15, 1981). “Cis-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of pH-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate,”Biochem. Biophys. Res. Commun. 102(3):1048-1054.
Stephan, J-P. et al. (1999). “Distribution and Function of the Adhesion Molecule BEN During Rat Development,”Dev. Biol. 212:264-277.
Stephan, J-P. et al. (1999). “Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation,”Endocrinology140(12):5841-5854.
Sulman, E.P. et al. (Mar. 1, 1997). “ECK, A HumanEPH-Related Gene, Maps to 1p36.1, a Common Region of Alteration in Human Cancers,”Genomics40(2):371-374.
Trouet, A. et al. (Jan. 1982). “A Covalent Linkage Between Daunorubicin and Proteins that is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-Carrier Conjugate: In vitro and in vivo Studies,”Proc. Natl. Acad. Sci. USA79(1):626-629.
Verhoeyen, M. et al. (1988). “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,”Science239:1534-1536.
Walker-Daniels, J. et al. (1999). “Overexpression of the EphA2 Tyrosine Kinase in Prostate Cancer,”Prostate41:275-280.
Walker-Daniels, J. et al. (Nov. 2002). “c-Cbl-Dependent EphA2 Protein Degradation Is Induced by Ligand Binding,”Mol. Cancer Res. 1:79-87.
Weiner, L.M. et al. (2001). “Therapeutic Monoclonal Antibodies: General Principles,” Chapter 20, Section 5In Cancer: Principles and Practice of Oncology, Sixth Edition, Freeman, S. et al. eds, Lippincott Williams & Wilkins, pp. 495-508.
Wheatley, S.P. et al. (1998). “Indirect Immunofluorescence Microscopy in Cultured Cells” Chapter 18In Animal Cell Culture Methods:Methods in Cell Biology, Mather, J.P. et al. eds., Academic Press, vol. 57, pp. 313-332.
Winter, G. et al. (Jan. 24, 1991). “Man-Made Antibodies,”Nature349:293-299.
Winter, G. et al. (1994). “Making Antibodies by Phage Display Technology,”Annu. Rev. Immunol. 12:433-455.
Woodruff, T.K. (1998). “Cellular Localization of mRNA and Protein: In Situ Hybridization Histochemistry and in Situ Ligand Binding,” Chapter 19In Animal Cell Culture Methods: Methods in Cell Biology, Mather, J.P. et al. eds., Academic Press, vol. 57, pp. 333-351.
Wu, X. et al. (May 25, 2000). “ATM Phosphoryla

Affiliated with

Also associated with

Rating

Antibodies that bind to EphA2 and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies that bind to EphA2 and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind to EphA2 and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4071969